Blueprint Medicines Corporation (BPMC) Stock Faces Lower Risks Forward After Forming Double Top Chart Pattern

April 21, 2018 - By Maria Brooks

Blueprint Medicines Corporation (NASDAQ:BPMC) Logo

The chart of Blueprint Medicines Corporation (BPMC) shows a double top with $87.70 target or 7.00 % above today’s $81.96 share price. The 7 months chart pattern indicates low risk for the $3.58 billion company. It was reported on Apr, 21 by Finviz.com. If the $87.70 price target is reached, the company will be worth $250.74M more. Double tops are rare but powerful chart patterns.

The stock decreased 1.55% or $1.29 during the last trading session, reaching $81.96. About 403,993 shares traded or 9.71% up from the average. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 101.73% since April 21, 2017 and is uptrending. It has outperformed by 90.18% the S&P500.

Analysts await Blueprint Medicines Corporation (NASDAQ:BPMC) to report earnings on May, 2. They expect $-1.09 earnings per share, down 29.76 % or $0.25 from last year’s $-0.84 per share. After $-1.23 actual earnings per share reported by Blueprint Medicines Corporation for the previous quarter, Wall Street now forecasts -11.38 % EPS growth.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Coverage

Among 8 analysts covering Blueprint Medicines (NASDAQ:BPMC), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicines had 11 analyst reports since October 23, 2017 according to SRatingsIntel. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, November 13 by BTIG Research. Jefferies maintained Blueprint Medicines Corporation (NASDAQ:BPMC) rating on Friday, December 22. Jefferies has “Buy” rating and $88.0 target. The firm has “Buy” rating given on Wednesday, November 1 by Canaccord Genuity. The firm has “Buy” rating given on Monday, November 6 by Wedbush. The firm has “Buy” rating given on Monday, December 11 by Goldman Sachs. Wedbush maintained it with “Buy” rating and $10600 target in Monday, April 16 report. The rating was maintained by BTIG Research with “Buy” on Tuesday, October 31. JMP Securities maintained the shares of BPMC in report on Monday, April 16 with “Buy” rating. Canaccord Genuity maintained the shares of BPMC in report on Monday, April 16 with “Buy” rating. The firm earned “Overweight” rating on Monday, October 23 by Morgan Stanley.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: